CNRS UMR 5235, University Montpellier, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
Department of Medical Protein Research, Flanders Institute for Biotechnology, Ghent University, Faculty of Medicine and Health Sciences, Ghent, BE 9000, Belgium.
Cytokine Growth Factor Rev. 2015 Apr;26(2):179-82. doi: 10.1016/j.cytogfr.2014.10.006. Epub 2014 Oct 31.
In this short review, we summarize how insights into the structure and dynamics of interferon-receptor complex assembly and activation guided the design of a novel class of engineered type I interferons that combine a largely lost potency on non-targeted cells with high activity on targeted cells. These novel interferons are expected to exhibit lower systemic toxicities compared to other interferon therapy modalities and could open avenues to revive these cytokines for the treatment of patients suffering of cancer and viral infections.
在这篇简短的综述中,我们总结了干扰素受体复合物组装和激活结构与动力学方面的研究进展如何指导新型工程化 I 型干扰素的设计,这些干扰素在非靶细胞上的效力大大丧失,但在靶细胞上具有很高的活性。与其他干扰素治疗方式相比,这些新型干扰素预计具有更低的全身毒性,并且可能为这些细胞因子重新用于治疗癌症和病毒感染患者开辟道路。